CD137- and DLL3-targeting multispecific antigen-binding molecules

Patent metadata

Field	Value
Publication number	US-11718672-B2
Application number	US-202217670917-A
Country	US
Kind code	B2
Filing date	Feb 14, 2022
Priority date	Mar 31, 2020
Publication date	Aug 8, 2023
Grant date	Aug 8, 2023

Abstract

The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising
(1) a multispecific antigen-binding molecule that comprises:
(a) a first antigen-binding moiety and a second antigen-binding moiety, at least one of which binds to human CD137 and comprises an antibody variable region comprising a heavy chain CDR 1 comprising SEQ ID NO: 20, a heavy chain CDR 2 comprising SEQ ID NO: 34, a heavy chain CDR 3 comprising SEQ ID NO: 48, a light chain CDR 1 comprising SEQ ID NO: 63, a light chain CDR 2 comprising SEQ ID NO: 68, and a light chain CDR 3 comprising SEQ ID NO: 73; and
(b) a third antigen-binding moiety that binds to human Delta-like 3 (DLL3) and comprises an antibody variable region comprising a heavy chain CDR1 comprising SEQ ID NO: 233, a heavy chain CDR 2 comprising SEQ ID NO: 234, a heavy chain CDR 3 comprising SEQ ID NO: 235, a light chain CDR 1 comprising SEQ ID NO: 237, a light chain CDR 2 comprising SEQ ID NO: 238, and a light chain CDR 3 comprising SEQ ID NO: 239; and

(2) a pharmaceutically acceptable carrier.

2. A pharmaceutical composition comprising
(1) a multispecific antigen-binding molecule that comprises:
(a) a first antigen-binding moiety and a second antigen-binding moiety, at least one of which binds to human CD137 and comprises an antibody variable region comprising a VH comprising SEQ ID NO: 6 and a VL comprising SEQ ID NO: 58; and
(b) a third antigen-binding moiety comprising an antibody variable region comprising a VH comprising SEQ ID NO: 232 and a VL comprising SEQ ID NO: 236; and

(2) a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 1 , wherein the antibody variable regions of the first and second antigen binding moieties are identical.

4. The pharmaceutical composition of claim 2 , wherein the antibody variable regions of the first and second antigen binding moieties are identical.

5. The pharmaceutical composition of claim 3 , wherein each of the first and second antigen-binding moieties is a Fab that has a cysteine residue at EU numbering position 191, and wherein a disulfide bond links these two cysteine residues.

6. The pharmaceutical composition of claim 4 , wherein each of the first and second antigen-binding moieties is a Fab that has a cysteine residue at EU numbering position 191, and wherein a disulfide bond links these two cysteine residues.

7. The pharmaceutical composition of claim 5 , wherein each of the first, second and third antigen binding moieties is in the form of a Fab comprising a VH, a VL, a CH1 domain and a light chain constant (CL) domain, and wherein the C-terminus of the CH1 domain of the third antigen-binding moiety is fused, directly or via a peptide linker, to the N-terminus of the VH of either the first antigen binding moiety or the second antigen binding moiety.

8. The pharmaceutical composition of claim 6 , wherein each of the first, second and third antigen binding moieties is in the form of a Fab comprising a CH1 domain and a light chain constant (CL) domain, and wherein the C-terminus of the CH1 domain of the third antigen-binding moiety is fused, directly or via a peptide linker, to the N-terminus of the VH of either the first antigen binding moiety or the second antigen binding moiety.

9. The pharmaceutical composition of claim 7 , wherein the fusion is via a peptide linker that comprises an amino acid sequence selected from the group consisting of following: SEQ ID NO: 248, SEQ ID NO: 249, and SEQ ID NO: 259.

10. The pharmaceutical composition of claim 8 , wherein the fusion is via a peptide linker that comprises an amino acid sequence selected from the group consisting of following: SEQ ID NO: 248, SEQ ID NO: 249, and SEQ ID NO: 259.

11. The pharmaceutical composition of claim 9 , wherein the third antigen binding moiety is a crossover Fab in which the VH is linked to the CL domain and the VL is linked to the CH1 domain, and wherein each of the first and second antigen binding moieties is a conventional Fab in which the VH is linked to the CH1 domain and the VL is linked to the CL domain.

12. The pharmaceutical composition of claim 10 , wherein the third antigen binding moiety is a crossover Fab in which the VH is linked to the CL domain and the VL is linked to the CH1 domain, and wherein each of the first and second antigen binding moieties is a conventional Fab in which the VH is linked to the CH1 domain and the VL is linked to the CL domain.

13. The pharmaceutical composition of claim 11 , wherein, in the CL domain of each of the first and second antigen binding moieties, the amino acids at Kabat numbering positions 123 and 124 are arginine and lysine, respectively; and wherein, in the CH1 domain of each of the first and second antigen binding moieties, the amino acid at each of EU numbering positions 147 and 213 is glutamic acid.

14. The pharmaceutical composition of claim 12 , wherein, in the CL domain of each of the first and second antigen binding moieties, the amino acids at Kabat numbering positions 123 and 124 are arginine and lysine, respectively; and wherein, in the CH1 domain of each of the first and second antigen binding moieties, the amino acid at each of EU numbering positions 147 and 213 is glutamic acid.

15. The pharmaceutical composition of claim 13 , wherein the multispecific antigen-binding molecule further comprises an Fc domain.

16. The pharmaceutical composition of claim 14 , wherein the multispecific antigen-binding molecule further comprises an Fc domain.

17. The pharmaceutical composition of claim 15 ,
wherein the Fc domain comprises a first and a second Fc region subunit,
wherein the first Fc-region subunit is selected from the group comprising following:
an Fc region polypeptide comprising alanine at each of positions 234 and 235;
an Fc region polypeptide comprising alanine at each of positions 234, 235, and 297; and
an Fc region polypeptide comprising alanine at each of positions 234, 235, and 297, cysteine at position 354, and tryptophan at position 366;

wherein the second Fc-region subunit is selected from the group comprising following:
an Fc region polypeptide comprising alanine at each of positions 234 and 235;
an Fc region polypeptide comprising alanine at each of positions 234, 235, and 297; and
an Fc region polypeptide comprising alanine at each of positions 234, 235, and 297, cysteine at position 349, serine at position 366, alanine at position 368, and valine at position 407; and

wherein all of the above Fc region positions are by EU numbering.

18. The pharmaceutical composition of claim 16 ,
wherein the Fc domain comprises a first and a second Fc region subunit,
wherein the first Fc-region subunit is selected from the following:
an Fc region polypeptide comprising alanine at each of positions 234 and 235;
an Fc region polypeptide comprising alanine at each of positions 234, 235, and 297; and
an Fc region polypeptide comprising alanine at each of positions 234, 235, and 297, cysteine at position 354, and tryptophan at position 366;

wherein the second Fc-region subunit is selected from the following:
an Fc region polypeptide comprising alanine at each of positions 234 and 235;
an Fc region polypeptide comprising alanine at each of positions 234, 235, and 297; and
an Fc region polypeptide comprising alanine at each of positions 234, 235, and 297, cysteine at position 349, serine at position 366, alanine at position 368, and valine at position 407; and

wherein all of the above Fc region positions are by EU number

Assignees

• Chugai Pharmaceutical Co Ltd
• Chugai Seiyaki Kk

Inventors

• Naoi Sotaro
• Feng Shu
• Igawa Tomoyuki
• Ho Shu Wen Samantha

Classifications

• C07K16/2809 Primary

  against the T-cell receptor (TcR)-CD3 complex · CPC title

• C07K16/28

  against receptors, cell surface antigens or cell surface determinants · CPC title

• C07K16/2878 Primary

  against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/31

  multispecific · CPC title